Feasibility of a novel wearable thermal device for management of bothersome hot flashes in patients with prostate cancer

Author:

Peeke Pamela1,Billes Sonja1ORCID,Vetter Andrew1,Naghavi Nader1,Le Diana2,Smith Matthew3,Morgans Alicia4ORCID

Affiliation:

1. Embr Labs, Inc.

2. Kelly Statistical Consulting

3. Embr Labs

4. Dana-Farber Cancer Institute

Abstract

Abstract BACKGROUND This single-arm prospective study evaluated the feasibility of a novel wrist-worn thermal device that applies cooling to the inside of the wrist for management of bothersome hot flashes in prostate cancer survivors. METHODS 57 individuals were enrolled and instructed to use the device as needed for 4 weeks. The primary outcome was thermal device usage (hours and sessions per day). Additional outcomes included the change in patient reported Hot Flash Related Daily Interference Scale (HFRDIS, range 0–10) and Patient Reported Outcomes Measurement Information System Sleep Disturbance 4a (PROMIS SD T-score, range 0-100) and Sleep Related Impairment 8a (PROMIS SRI T-score, range 0-100). Study procedures were conducted remotely from May to Dec 2021 in the US. RESULTS 44 participants completed the study and 39 had retrievable usage data. The mean ± SD age was 67 ± 6 years and 5 ± 5 years since cancer diagnosis. Baseline scores indicated moderate hot flash interference (HFRDIS mean ± SD: 4.3 ± 2.0) and mild sleep disturbance (PROMIS SD: 56.4 ± 6.7). Mean ± SD use of the thermal device was 3.2 ± 2.5 hours/day and 7.6 ± 3.6 sessions/day. Most (67%) participants reported using the device 7 days/nights each week. Statistically significant improvements from baseline at Week 4 were observed for HFRDIS (mean ± SE change: -1.1 ± 0.3), PROMIS SD (-6.0 ± 1.0), and PROMIS SRI (-5.5 ± 1.2) scores (all p < .001). Improvements were also observed in subjective measures of hot flashes and night sweats. The majority (69%) of participants reported that the thermal device was effective at helping them manage hot flashes. No adverse events were reported. CONCLUSIONS Results support the feasibility of using the thermal device for management of bothersome hot flashes in prostate cancer survivors. Future randomized controlled studies are warranted to evaluate patient reported outcomes related to frequency and severity of hot flashes, sleep quality, fatigue, and overall quality of life.

Publisher

Research Square Platform LLC

Reference38 articles.

1. Cancer statistics, 2023;Siegel RL;CA Cancer J Clin,2023

2. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, et al. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol 83, 267–293 (2023)

3. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update;Virgo KS;J Clin Oncol,2021

4. Sharifi N, Gulley JL & Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 294, 238 – 44 (2005)

5. Managing hot flushes in men after prostate cancer–a systematic review;Frisk J;Maturitas,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3